Novavax | NVAX - Current Assets


Novavax reported $978.28M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Adma Biologics USD 466.51M 63.86M Dec/2025
Agenus USD 133.44M 514K Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
Cassava Sciences USD 97.71M 11.2M Dec/2025
Geron USD 520.27M 2.07M Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
MannKind USD 291.58M 67.26M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Moderna USD 6.54B 54M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Novavax USD 978.28M 3.69M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
TG Therapeutics USD 630.76M 31M Dec/2025